Articles On MGC Pharmaceuticals (ASX:MXC)

MGC Pharmaceuticals Ltd (ASX: MXC) has reported that the number of patients being prescribed its cannabinoid medicines has now passed the key milestone of 600 in Australia & the United Kingdom. Prescriptions were 400 at the end of Sep...

Agri-tech business Roots Sustainable Agricultural Technologies (ASX:ROO) says its crop-cooling technology continues to gain traction with commercial cannabis producers. The Israeli-based company released results from the operation of its Ro...

The Althea Group Holdings Ltd (ASX: AGH) share price has been a positive performer on Wednesday. In morning trade the cannabis company’s shares are up 8% to 68.5 cents. Why is the Althea share price on the rise? This morning Althea release...

It appears leading Canadian cannabis business Canopy Growth Corp didn’t get the ‘buy low, sell high’ pot stock memo after dumping its 42.08 million shares in Auscann Group Holdings Ltd (ASX: AC8) for just 15 cents per share.  The block tra...

2018 witnessed several catalysts for the legal cannabis industry, with countries legalising medicinal cannabis, public and private sector getting into constructive discussions about the calibre and cons of the pot industry from a business p...

Cannabis industry is composed of ancillary products and services, legal cultivators and producers, consumers, researchers, independent industrial standard bodies and regulators. Lately, several companies are getting inclined towards the can...

The Althea Group Holdings Ltd (ASX: AGH) share price is on course to end the week on a high. In early trade the cannabis company’s shares are up almost 10% to 68 cents. Why is the Althea share price charging higher? This morning Althea pro...

Special Report: MGC’S strategic focus on building out its global distribution network is starting to pay dividends, as sales ramped up in the second half of September. It’s been a good month for medicinal cannabis stock MGC Pharma (ASX: MXC...

It has been a busy day in the Australian cannabis industry with a series of an announcements being made this morning. Here’s what has been happening today: BOD Australia Ltd (ASX: BDA) This morning this medicinal cannabis healthcare produc...

This week, the 33 cannabis (and cannabis-adjacent) stocks tracked by Stockhead posted an average weekly return of 3 per cent. That’s against a broader downtrend for the sector, with the BI Global Cannabis Competitive Peers index down 40 per...

MGC Pharmaceuticals has now passed 200 patients that have prescribed for or will be prescribing for its medical cannabis-based products.

Special Report: MGC Pharma’s flagship epilepsy drug CannEpil will be the subject of yet another clinical trial after Australia’s ethics body approved a new study. MGC (ASX:MXC) will conduct a head-to-head clinical study on severe intractabl...

MGC Pharmaceuticals will carry out a clinical study comparing the effectiveness of its medical cannabis products for the treatment of severe epilepsy.

The MGC Pharmaceuticals Ltd (ASX: MXC) share price has pushed higher in morning trade following the release of a positive announcement. At the time of writing the cannabis company’s shares are up 2.5% to 4 cents. Why is the MGC Pharma shar...

The Cann Global Ltd (ASX: CGB) share price has been a big mover on the Australian share market on Thursday. The cannabis company’s shares are up 16% to 2.9 cents in afternoon trade following the release of a positive update. What did Cann...

MGC Pharmaceuticals is collaborating with the Slovenian Institute of Hop Research and Brewing on a large-scale medical cannabis research project.

Medicinal pot stock Cann Group (ASX:CAN) is planning to go large at its Mildura-based cannabis manufacturing facility. The company announced revised construction plans this morning which will see an extra production room added, along with d...

The increasing use of medical cannabis products has prompted many countries to soften the regulations regarding the manufacturing and consumption of cannabis products. Last year, Canada became the second and the largest country in the world...

MGC Pharmaceuticals is hoping to overturn legislation that forbids medical cannabis users from driving.

‘Pot stocks’ were making headlines in 2018. California, one of the world’s biggest economies and the most populous state in the US, finally enacted legislation to legalise the recreational use of cannabis. It joined a growing list of US st...

The company is actively progressing towards a listing on the London Stock Exchange in the second half of calendar year 2019.

MGC Pharmaceuticals is planning to list on the London Stock Exchange in the second half of the 2019 calendar year.

Special Report: MGC Pharma has significantly boosted its cash position ahead of a big second half of the calendar year, including a listing on the London Stock Exchange. Seed-to-pharmacy biotech MGC Pharma (ASX:MXC) has successfully raised...

Recently, Barbados, a Caribbean country, has introduced the Medicinal Cannabis Industry Act. If passed, it intends to open doors for the medicinal cannabis in the small country. Besides, the bill has proposed to set up a Licensing Authority...

On Stockhead today, the disconnect between federal and state governments on coal, private equity deals are rising and an ‘avalanche’ is laying waste to lithium prices. But first, here’s what you need to know.   The day ahead Data Today the...

The healthcare industry of Australia is a key contributor in developing the economy. The companies who are in this industry, have to update them with the new medicine for the treatment of the diseases. The healthcare space of Australia is p...

The legalisation of medical cannabis in southeast Asia is gathering steam with news that Thailand has officially started distributing cannabis oil to eligible patients over the past week. Advocates hope that the move is a sign of things to...

Australia has a well-regulated and high-quality health sector, while its medical research and healthcare infrastructure is of world class. Over the years, the health and medical industry in the country has grown at a rapid pace in terms of...

At time of writing, the share price of MGC Pharmaceuticals Ltd [ASX:MXC] is holding steady at 5.3 cents. The company spiked in late in 2017, along with other ASX-listed cannabis companies... The post A Look at the MGC Pharmaceuticals Share...

MGC Pharmaceuticals now has 100 patients that have been prescribed or will be prescribed its medical cannabis-based products.

MGC Pharmaceuticals will start construction of its large-scale medical cannabis facility in Malta during in the current quarter.

Special Report: Making good on its promises, bio-pharma company MGC Pharma has signed a long-term lease agreement on the 6,000sqm site for its production and research facility in Malta. The news is a massive step for MGC Pharmaceuticals (AS...

MGC Pharmaceuticals (ASX: MXC) is establishing a key gateway into the potentially lucrative European cannabis market with the construction of a new production facility in Malta. The Australian company has signed a long-term lease agreemen...

The MGC Pharmaceuticals Ltd (ASX: MXC) share price could be on the move today after the cannabis company released a late announcement on Thursday. What did MGC Pharmaceuticals announce? On Thursday MGC Pharmaceuticals provided an update on...

The federal government has taken steps to cut red tape and speed up the granting of licences for Australia’s cannabis players. Health Minister Greg Hunt said the federal government would boost the nation’s medicinal cannabis industry by pri...

MGC Pharmaceuticals will sell its nutraceutical products in China through YuShop Global’s online platform and retail partners.

Medicinal cannabis company Cannvalate is getting its ducks in a row ahead of its planned IPO, strengthening its board with the appointment of Dr Amit Vohra as chief operating officer. Dr Vohra was formerly the head of strategy and health so...

Got 90 seconds? Then listen to MGC Pharmaceuticals co-founder and managing director, Roby Zomer discuss the company’s latest research announcement. MGC Pharmaceuticals (ASX:MXC) is a global biopharma company focused on developing and supply...

Today, we hear from Maxim Jacobs, managing partner at New York-based Edison Investment Research.   What’s hot? Jacobs told Stockhead the hottest sector “by far” is cannabis. “While some people may consider it to be a bubble there is a subst...

North American cannabis stocks have been rocked by scandal lately. Regulatory deadlocks, smaller than expected returns, illegal growing and weaker than expected earnings is having a major effect on share prices. One of the biggest shocks to...

Got 90 seconds? Then listen to Edison Investment Research managing partner Maxim Jacobs discuss the medicinal cannabis sector and MGC Pharmaceuticals. Edison is an investment research and advisory company, with offices in North America, Eur...

Impression Healthcare (ASX: IHL) has tweaked its internal structure by appointing Dr Sud Agarwal, a leading figure in the medicinal cannabis industry as its Chief Medical Officer and non-executive director. The newly appointed executive is...

The use of medicinal cannabis is extending, and the developments appear to be favourable for the community. In this article, we would discuss the two stocks from the flourishing industry – cannabis. One of the stocks – MXC has come up with...

Sponsored Content There may be some hope yet for sufferers of glioblastoma, an extremely aggressive type of brain cancer for which there is no cure. New research from MGC Pharma (ASX:MXC) in conjunction with Slovenia’s National Institute of...

MGC Pharmaceuticals’ cannabinoid formulations may hold the key for treating some of the most aggressive brain cancers.

Biopharmaceutical company MGC Pharmaceuticals (ASX: MXC) has completed what it calls “ground-breaking research” that highlights the effectiveness of cannabinoids on various brain cancers. Earlier today, the “seed to pharmacy” bio-pharma com...

Special Report: New research from MGC Pharma might hold the key to treating glioblastoma, an extremely aggressive type of brain cancer for which there is no cure. A full report on pre-clinical research, conducted by MGC Pharma (ASX:MXC) in...

Taking the cannabis market to the next level, the US is now taking a closer look at the industry’s lack of access to financial services. Forbes reported on Tuesday that a Republican-controlled Senate committee had scheduled a hearing for ne...

Is the world progressing at a pace that it would “go green” when it comes to legalizing of cannabis? The controversy that this topic of taboo holds for the globe is paramount and never-ending; but lately, there has been paradigm shift and a...

Special Report: A strong June quarter has seen a substantial increase in revenue for the European-based seed-to-pharmacy biotech company. MGC Pharma (ASX:MXC) has overseen a substantial increase in sales during the quarter, rapidly advancin...